Pfizer Picks 'Off-The-Shelf' CAR-T And Backs TALEN Over CRISPR
This article was originally published in Scrip
"Not as good as TALEN," was Cellectis's verdict on CRISPR gene editing, and it appears Pfizer concurs. The big pharma has licensed Cellectis's lead TALEN (not CRISPR) gene-edited CAR-T product candidate UCART19. Servier held an option on the rights, but exercised it early and handed it straight over to Pfizer.
Register for our free email digests: